EFFICACY OF LY333328 AGAINST EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS

Authors
KAATZ GW SEO SM AESCHLIMANN JR HOULIHAN HH MERCIER RC RYBAK MJ
Citation
Gw. Kaatz et al., EFFICACY OF LY333328 AGAINST EXPERIMENTAL METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS ENDOCARDITIS, Antimicrobial agents and chemotherapy, 42(4), 1998, pp. 981-983
Citations number
16
Categorie Soggetti
Pharmacology & Pharmacy",Microbiology
Journal title
Antimicrobial agents and chemotherapy → ACNP
ISSN journal
00664804
Volume
42
Issue
4
Year of publication
1998
Pages
981 - 983
Database
ISI
SICI code
0066-4804(1998)42:4<981:EOLAEM>2.0.ZU;2-K
Abstract
The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was c ompared with that of vancomycin by using the rabbit model of left-side d methicillin-resistant Staphylococcus aureus endocarditis. Animals re ceived LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h , respectively) for 4 days. These drugs were equally effective in clea ring bacteremia and in reducing bacterial counts in vegetations and ti ssues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.